A phase 2a, randomised, double-blind, placebo-controlled, cross-over, single and multiple dose study to assess the effects of imeglimin on nicotine-induced endothelial dysfunction in young non-smoker healthy male subjects
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
Price : $35 *
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Poxel
- 26 Sep 2018 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2017 The results from this study are anticipated in the second half of 2017, as reported in a Poxel media release.